Alnylam Pharmaceuticals, Inc. (ALNY) Earnings History
Profitable24 years of earnings data (2002–2025) · Positive TTM net income
Loading earnings history...
Alnylam Pharmaceuticals, Inc. (ALNY) Earnings Overview
As of October 3, 2026, Alnylam Pharmaceuticals, Inc. (ALNY) reported trailing twelve-month net income of $808M, reflecting +206.9% year-over-year growth. The company earned $5.84 per diluted share over the past four quarters, with a net profit margin of 8.4%.
Looking at the long-term picture, ALNY's historical earnings data spans multiple years. The company achieved its highest annual net income of $314M in fiscal 2025, representing a new all-time high.
Alnylam Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 81.8%, operating margin of 13.5%, and net margin of 8.4%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including IONS (-$565M net income, -40.4% margin), ARWR (-$320M net income, -0.2% margin), NTLA (-$400M net income, -609.9% margin), ALNY has outperformed on profitability metrics. Compare ALNY vs IONS →
ALNY Earnings vs Peers
Earnings metrics vs comparable public companies
ALNY Historical Earnings Data (2002–2025)
24 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $314M | +212.8% | $502M | $2.33 | 8.4% | 13.5% |
| 2024 | -$278M | +36.8% | -$177M | $-2.18 | -12.4% | -7.9% |
| 2023 | -$440M | +61.1% | -$282M | $-3.52 | -24.1% | -15.4% |
| 2022 | -$1.13B | -32.6% | -$785M | $-9.30 | -109.0% | -75.7% |
| 2021 | -$853M | +0.6% | -$709M | $-7.20 | -101.0% | -83.9% |
| 2020 | -$858M | +3.1% | -$828M | $-7.46 | -174.1% | -168.1% |
| 2019 | -$886M | -16.4% | -$939M | $-8.11 | -403.2% | -427.5% |
| 2018 | -$761M | -55.1% | -$815M | $-7.57 | -1016.6% | -1087.6% |
| 2017 | -$491M | -19.7% | -$500M | $-5.42 | -545.9% | -556.2% |
| 2016 | -$410M | -41.4% | -$425M | $-4.79 | -869.6% | -900.3% |
| 2015 | -$290M | +19.5% | -$296M | $-3.45 | -705.8% | -720.3% |
| 2014 | -$360M | -303.9% | -$405M | $-4.85 | -712.8% | -801.0% |
| 2013 | -$89M | +15.8% | -$93M | $-1.45 | -189.2% | -197.0% |
| 2012 | -$106M | -83.9% | -$129M | $-2.11 | -158.9% | -194.0% |
| 2011 | -$58M | -32.5% | -$55M | $-1.36 | -69.7% | -66.2% |
| 2010 | -$44M | +8.6% | -$44M | $-1.04 | -43.5% | -44.1% |
| 2009 | -$48M | -81.3% | -$48M | $-1.14 | -47.3% | -47.9% |
| 2008 | -$26M | +69.3% | -$28M | $-0.64 | -27.3% | -28.9% |
| 2007 | -$85M | -147.0% | -$93M | $-2.21 | -167.9% | -183.1% |
| 2006 | -$35M | +19.4% | -$40M | $-1.09 | -128.5% | -146.7% |
| 2005 | -$43M | -31.4% | -$43M | $-1.96 | -750.8% | -760.5% |
| 2004 | -$33M | -30.4% | -$32M | $-2.75 | -763.3% | -754.2% |
| 2003 | -$25M | -505.2% | -$25M | $-26.56 | -14223.3% | -14236.9% |
| 2002 | -$4M | - | -$4M | $-12.48 | - | - |
Download Data
Export ALNY earnings history in CSV or JSON format
Free sign-in required to download data
ALNY Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
24+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ALNY — Frequently Asked Questions
Quick answers to the most common questions about buying ALNY stock.
What is ALNY earnings per share (EPS)?
ALNY trailing twelve-month (TTM) diluted EPS is $5.84, reflecting +206.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2002 to 2025 is available in the table on this page.
What is Alnylam Pharmaceuticals, Inc.'s net income?
Alnylam Pharmaceuticals, Inc. (ALNY) trailing twelve-month net income is $808M as of 2025. Earnings grew +206.9% year-over-year.
Is ALNY profitable?
Yes, ALNY is profitable with a TTM net income of $808M and a net profit margin of +8.4%.
What is ALNY's earnings growth rate?
ALNY compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2002 to 2025.
What are ALNY's profit margins?
Alnylam Pharmaceuticals, Inc. net profit margin is +8.4%, operating margin is +13.5%, and gross margin is +81.8%. Margins are within a typical range for the sector. Return on Equity is +73.3%.
Is ALNY growing earnings?
Yes, ALNY earnings are accelerating — EPS growth of +206.9% exceeds the 5-year CAGR of N/A. TTM net income reached $808M. Earnings momentum is strengthening.
What was ALNY's best earnings year?
Alnylam Pharmaceuticals, Inc.'s highest annual net income on record is $314M, achieved in fiscal year 2025. Earnings history on this page spans 2002 to 2025 and includes all annual and quarterly figures.
What were ALNY's earnings last quarter?
ALNY's most recent reported quarter was Q2 2026. Net income was $164M with diluted EPS of $1.20. For a full breakdown of all quarters, see the quarterly earnings table on this page.